博舒替尼对甲状腺乳头状癌B-CPAP细胞恶性行为的影响及其机制*

doi:10.12047/j.cjap.6373.2022.133

中国应用生理学杂志 ›› 2022, Vol. 38 ›› Issue (6): 730-734.doi: 10.12047/j.cjap.6373.2022.133

博舒替尼对甲状腺乳头状癌B-CPAP细胞恶性行为的影响及其机制^*

夏湖斌¹, 万文珺¹, 王羽², 张一帆¹, 曹文卓¹, 李曙^1△, 吴超^1△

1.皖南医学院病理生理学教研室, 安徽芜湖 241002;
2.皖南医学院第二附属医院肾内科, 安徽芜湖 241002

收稿日期:2022-10-18 修回日期:2022-11-25 出版日期:2022-11-28 发布日期:2023-06-12
通讯作者: ^△Tel: 0553-3932616; E-mail: wylishu@wnmc.edu.cn, 15656078923@163.com
基金资助:
^* 安徽省高校科学研究重大项目(KJ2020ZD55);安徽省高校科学研究重点项目(KJ2020A0604);安徽省重点研究与开发计划项目(S202104j07020117);国家级大学生创新训练计划项目(202110368031);皖南医学院横向科研项目(22050123004)

Effects of bosutinib on the malignant behavior of thyroid papillary carcinoma B-CPAP cells and its mechanisms

XIA Hu-bin¹, WAN Wen-jun¹, WANG Yu², ZHANG Yi-fan¹, CAO Wen-zhuo¹, LI Shu^1△, WU Chao^1△

1. Department of Pathophysiology, Wannan Medical College, Wuhu 241002;
2. Department of Nephrology, the Second Affiliated Hospital of Wannan Medical College, Wuhu 241002, China

Received:2022-10-18 Revised:2022-11-25 Online:2022-11-28 Published:2023-06-12

摘要/Abstract

摘要： 目的: 探讨博舒替尼对甲状腺乳头状癌B-CPAP细胞恶性行为的影响及其可能的作用机制。 方法: 体外培养甲状腺乳头状癌B-CPAP细胞系,加入浓度梯度(1、2、3、4和5 μmol/L)博舒替尼干预24 h,用DMSO作为对照组,每组设5个平行复孔。采用CCK-8法检测细胞增殖能力,Transwell实验和划痕修复实验检测细胞侵袭和迁移能力,TUNEL染色实验和流式细胞术检测细胞凋亡情况,蛋白质印迹法检测自噬蛋白(Beclin-1、LC3、p62)表达情况和信号通路蛋白(SIK2,p-mTOR、mTOR 、p-ULK1、ULK1)表达情况。 结果: 与对照组比较,博舒替尼2、3、4和5 μmol/L浓度组细胞增殖活性、迁移能力和侵袭能力均降低(P＜0.01)而细胞凋亡率均增加(P＜0.01),博舒替尼4和5μmol/L浓度组Beclin-1(P＜0.05)、LC3-Ⅱ/LC3-Ⅰ(P＜0.05)、SIK2(P＜0.01)和p-ULK1(P＜0.01)蛋白表达量均减少而p62(P＜0.05)和p-mTOR(P＜0.01)蛋白表达量增加。结论: 博舒替尼可能通过 SIK2-mTOR-ULK1通路抑制甲状腺乳头状癌细胞自噬,来抑制其增殖、侵袭和迁移能力并促进凋亡,从而减弱其恶性行为。

关键词: 甲状腺乳头状癌, 博舒替尼, 自噬, 恶性行为, 细胞培养

Abstract: Objective: To investigate the effects of bosutinib on the malignant behavior of thyroid papillary carcinoma B-CPAP cells and its possible mechanisms. Methods: Thyroid papillary carcinoma B-CPAP cells were cultured in vitro with a concentration gradient of(1、2、3、4 and 5 μmol/L)bosutinib intervened for 24 hours, DMSO was used as the control group. Five parallel compound holes were set in each group. Cell counting kit (CCK-8 method) method was used to detect cell proliferation. Transwell assay and cell wound healing assay were used to detect cell invasion and migration. TUNEL staining assay and flow cytometry were used to detect cell apoptosis. Western blot was used to detect the expressions of autophagic proteins (Beclin-1, LC3, p62) and signal pathway proteins (SIK2, p-mTOR, mTOR, p-ULK1, ULK1). Results: Compared with the control group, the cell proliferation activity, migration ability and invasion ability were decreased (P＜0.01), while the cell apoptosis rate was increased (P＜0.01) in the bosutinib concentration groups of 2, 3, 4 and 5 μmol/L . In the concentration groups of 4 and 5 μmol/L, the expression of Beclin-1 (P＜0.05), LC3- Ⅱ/LC3- Ⅰ (P＜0.05), SIK2 (P＜0.01) and p-ULK1 (P＜0.01) protein was decreased, while the expression of p62 (P＜ 0.05) and p-mTOR (P＜0.01) protein was increased. Conclusion: Bosutinib may inhibit the autophagy of thyroid papillary carcinoma cells through SIK2-mTOR-ULK1 signaling pathway to inhibit their proliferation, invasion and migration and promote apoptosis, thereby weakening their malignant behavior.

Key words: thyroid papillary carcinoma, Bosutinib, autophagy, malignant behavior, cell culture

中图分类号:

R736.1

夏湖斌, 万文珺, 王羽, 张一帆, 曹文卓, 李曙, 吴超. 博舒替尼对甲状腺乳头状癌B-CPAP细胞恶性行为的影响及其机制^*[J]. 中国应用生理学杂志, 2022, 38(6): 730-734.

XIA Hu-bin, WAN Wen-jun, WANG Yu, ZHANG Yi-fan, CAO Wen-zhuo, LI Shu, WU Chao. Effects of bosutinib on the malignant behavior of thyroid papillary carcinoma B-CPAP cells and its mechanisms[J]. CJAP, 2022, 38(6): 730-734.

参考文献

[1] Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(1): 17-29.
[2] 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献(电子版), 2019, 13(1): 7-21.
[3] 殷德涛, 韩飏, 张亚原, 等. 多灶性甲状腺乳头状癌的临床病理及颈淋巴结转移特征[J]. 中国普通外科杂志, 2017, 26(5):556-560.
[4] Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy[J]. J Hematol Oncol, 2018, 11(1): 84-98.
[5] Vultur A, Buettner R, Kowolik C, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells[J]. Mol Cancer Ther, 2008, 7(5): 1185-1194.
[6] Noguchi S, Shibutani S, Fukushima K, et al. Bosutinib, an SRC inhibitor, induces caspase-independent cell death associated with permeabilization of lysosomal membranes in melanoma cells.[J]. Vet Comp Oncol, 2018, 16(1): 69-76.
[7] Maes H, Rubio N, Garg AD et al. Autophagy: shaping the tumor microenvironment and therapeutic response[J]. Trends Mol Med, 2013, 19(7): 428-446.
[8] Nagayama Y, Zhao O . Autophagy and thyroid cancer[J]. J Cancer Metast Treat, 2021, 7(1): 81-96.
[9] Bieerkehazhi S, Chen Z, Zhao Y, et al. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling[J]. Oncotarget, 2017, 8(1): 1469-1480.
[10] Tan DS, Haaland B, Gan J, et al. Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer[J]. Mol Cancer, 13, 1(2014-01-24), 2014, 13(1): 13.
[11] Kim WG, Guigon CJ, Fozzatti L, et al. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer[J]. Clin Cancer Res, 2012, 18(5): 1281-1290.
[12] Kazakova D, Shimamura M, Kurashige T, et al. Re-evaluation of the role of autophagy in thyroid cancer treatment[J]. Endocr J, 2022, 69(7): 847-862.
[13] Katheder NS, Khezri R, O'Farrell F, et al. Microenvironmental autophagy promotes tumour growth[J]. Nature, 2017, 541(7637): 417-420.
[14] Chen F, Chen L, Qin Q, et al. Salt-inducible kinase 2: An oncogenic signal transmitter and potential target for cancer therapy[J]. Front Oncol, 2019, 9(2016): 18-24.
[15] Cao W, Li J, Yang K, et al. An overview of autophagy: Mechanism, regulation and research progress[J]. Bull Cancer, 2021, 108(3): 304-322.
[16] 许乐, 张霞, 吴超, 等. SIK2对心肌缺血/再灌注损伤大鼠能量代谢的影响及其机制[J]. 中国应用生理学杂志, 2022, 38(4): 304-307.
[17] 单尚然, 蒋方, 徐淑梅. β片层阻断肽H102对AD小鼠识别记忆能力和脑内AMPK-mTOR自噬相关通路的影响[J]. 中国应用生理学杂志, 2019, 35(1): 1-4.
[18] Ma L, Manaenko A, Ou YB, et al. Bosutinib attenuates inflammation via inhibiting salt-inducible kinases in experimental model of intracerebral hemorrhage on mice[J]. Stroke, 2017, 48(11): 3108-3116.

博舒替尼对甲状腺乳头状癌B-CPAP细胞恶性行为的影响及其机制^*

Effects of bosutinib on the malignant behavior of thyroid papillary carcinoma B-CPAP cells and its mechanisms

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	崔静轩, 龚治安, 张文天, 刘凯, 李铁, 邵淑丽, 张伟伟. 转录因子SIX2基因对牛骨骼肌卫星细胞增殖的影响^*[J]. 中国应用生理学杂志, 2022, 38(6): 622-627.
[2]	孔海军, 王凤华, 李新龙, 甘胜前, 谌晓安. PBMC线粒体自噬对高原移居人群运动能耗、线粒体呼吸链复合酶活性的影响^*[J]. 中国应用生理学杂志, 2022, 38(6): 655-659.
[3]	吕莹盈, 高巧婧, 张金梅, 李雪, 金毓, 王璐. 线粒体自噬对有氧运动干预大鼠抑郁的作用^*[J]. 中国应用生理学杂志, 2022, 38(6): 719-724.
[4]	王琪琪, 林巧, 单微燕, 张涛, 李昱蓉, 张云. 岩藻多糖诱导人骨肉瘤细胞143B损伤作用及其机制^*[J]. 中国应用生理学杂志, 2022, 38(6): 739-744.
[5]	张琳, 钱河, 赵宝生, 高曼棋, 刘玉珍. 敲低ACC1对胶质瘤U251细胞迁移的作用及机制研究^*[J]. 中国应用生理学杂志, 2022, 38(6): 745-753.
[6]	卓庆娅, 钱河, 赵宝生, 齐博, 刘玉珍. 普萘洛尔对人食管鳞癌细胞生物学功能的影响^*[J]. 中国应用生理学杂志, 2022, 38(6): 754-759.
[7]	钟锦, 史晋朝, 张倩, 孟金凤, 张倩倩, 李建国. Bdnf基因过表达慢病毒载体的构建及表达^*[J]. 中国应用生理学杂志, 2022, 38(5): 397-400.
[8]	陈丽, 陈金信, 王心怡, 李香兰, 姜海英. 组织蛋白酶K对大鼠空间学习记忆功能的影响^*[J]. 中国应用生理学杂志, 2022, 38(5): 412-417.
[9]	陈津子, 李旭艳, 刘东梅, 龙舒婷, 李永媚, 陈泓冰. 纳米ZnO对人肺上皮细胞BEAS-2B细胞增殖和凋亡的影响^*[J]. 中国应用生理学杂志, 2022, 38(5): 443-447.
[10]	方情, 马汝玉, 贺英昊, 齐敏友. 阿魏酸对高糖诱导的肾小球系膜细胞炎症及自噬水平的影响^*[J]. 中国应用生理学杂志, 2022, 38(5): 453-457.
[11]	郭佳, 李志东, 肖传实, 边云飞. PUMA对高糖诱导的大鼠H9C2心肌细胞凋亡的作用及机制^*[J]. 中国应用生理学杂志, 2022, 38(5): 504-509.
[12]	严惠, 赵虎, 李论. 1-磷酸鞘氨醇(S1P)对H9c2心肌细胞肥大反应的保护作用^*[J]. 中国应用生理学杂志, 2022, 38(5): 510-514.
[13]	褚智恒, 何施燕, 王瑜, 朱若婷, 顾益玲, 陈佳玉. 紫云英苷对未分化胃癌细胞凋亡的影响 ^*[J]. 中国应用生理学杂志, 2022, 38(5): 520-524.
[14]	陈懿婷, 褚智恒, 傅瑾雯 ,陶嘉颖, 陈佳玉. 大黄酸诱导胃癌细胞HGC-27凋亡的作用及其机制^*[J]. 中国应用生理学杂志, 2022, 38(5): 584-589.
[15]	刘凯, 孙新迪, 张伟伟, 杨清竹, 黄鑫, 邵淑丽. 利用CRISPRi下调 MDR1基因表达增强肺腺癌 A549/DDP细胞对顺铂敏感性^*[J]. 中国应用生理学杂志, 2022, 38(5): 590-594.